Topoisomerase II alpha antibody [C3], C-term
GTX100689
ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
TargetTOP2A
Overview
- SupplierGeneTex
- Product NameTopoisomerase II alpha antibody [C3], C-term
- Delivery Days Customer9
- Application Supplier NoteWB: 1:500-1:3000. IHC-P: 1:100-1:1000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration1 mg/ml
- ConjugateUnconjugated
- Gene ID7153
- Target nameTOP2A
- Target descriptionDNA topoisomerase II alpha
- Target synonymsTOP2, TOP2alpha, TOPIIA, TP2A, DNA topoisomerase 2-alpha, DNA gyrase, DNA topoisomerase (ATP-hydrolyzing), DNA topoisomerase II, 170 kD, DNA topoisomerase II, alpha isozyme, topoisomerase (DNA) II alpha 170kDa
- HostRabbit
- IsotypeIgG
- Protein IDP11388
- Protein NameDNA topoisomerase 2-alpha
- Scientific DescriptionThis gene encodes a DNA topoisomerase, an enzyme that controls and alters the topologic states of DNA during transcription. This nuclear enzyme is involved in processes such as chromosome condensation, chromatid separation, and the relief of torsional stress that occurs during DNA transcription and replication. It catalyzes the transient breaking and rejoining of two strands of duplex DNA which allows the strands to pass through one another, thus altering the topology of DNA. Two forms of this enzyme exist as likely products of a gene duplication event. The gene encoding this form, alpha, is localized to chromsome 17 and the beta gene is localized to chromosome 3. The gene encoding this enzyme functions as the target for several anticancer agents and a variety of mutations in this gene have been associated with the development of drug resistance. Reduced activity of this enzyme may also play a role in ataxia-telangiectasia. [provided by RefSeq]
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Li CJ, Tsai HW, Chen YL, et al. Cisplatin or Doxorubicin Reduces Cell Viability via the PTPIVA3-JAK2-STAT3 Cascade in Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2023,10:123-138. doi: 10.2147/JHC.S385238Read this paper
- Chen JC, Hsieh YY, Lo HL, et al. In Vitro and In Silico Mechanistic Insights into miR-21-5p-Mediated Topoisomerase Drug Resistance in Human Colorectal Cancer Cells. Biomolecules. 2019,9(9). doi: 10.3390/biom9090467Read this paper
- Liu TP, Hsieh YY, Chou CJ, et al. Systematic polypharmacology and drug repurposing via an integrated L1000-based Connectivity Map database mining. R Soc Open Sci. 2018,5(11):181321. doi: 10.1098/rsos.181321Read this paper
- Jeon KH, Yu HV, Kwon Y. Hyperactivated m-calpain affects acquisition of doxorubicin resistance in breast cancer cells. Biochim Biophys Acta Gen Subj. 2018,1862(5):1126-1133. doi: 10.1016/j.bbagen.2018.02.002Read this paper
- Lin ST, May EW, Chang JF, et al. PGRMC1 contributes to doxorubicin-induced chemoresistance in MES-SA uterine sarcoma. Cell Mol Life Sci. 2015,72(12):2395-409. doi: 10.1007/s00018-014-1831-9Read this paper
- Lin ST, Chou HC, Chang SJ, et al. Proteomic analysis of proteins responsible for the development of doxorubicin resistance in human uterine cancer cells. J Proteomics. 2012,75(18):5822-47. doi: 10.1016/j.jprot.2012.07.047Read this paper



![IHC-P analysis of human bladder tumor using GTX23111 Topoisomerase II alpha antibody [3F6]. Note intense nuclear staining of malignant cells and occasional mitotic figures.](https://www.genetex.com/upload/website/prouct_img/normal/GTX23111/GTX23111_20200811_IHC-P_111_w_23060620_252.webp)